Frequently Asked Questions
The global Pharmaceutical CRO and CDMO market was valued at USD 308.9 Billion in 2022.
The Pharmaceutical CRO and CDMO market is expected to grow at a CAGR of 1.30% between 2023 and 2030, reaching USD 338.13 Billion in 2030.
The largest market segment is API manufacturing, which accounted for 55.6% of the total market in 2022.
The largest market segment is phase III, which accounted for 44.2% of the total market 2022.
The fastest growing market segment is phase IV, expected to grow at the fastest CAGR from 2023 to 2030.
The largest market in 2022 was North America of the global Pharmaceutical CRO and CDMO market.
The top players include Catalent Inc., Recipharm AB, Jubilant Pharmova Ltd, Patheon Inc. (Thermo Fisher Scientific Inc.), Boehringer Ingelheim Group, Pfizer CentreSource, Aenova Holding GmbH, Famar SA, Baxter Biopharma Solutions (Baxter International Inc.), Lonza Group, Tesa Labtec GmbH (TESA SE), Tapemark, ARX LLC, CMIC Holdings Co. Ltd, LabCorp Drug Development, Syneos Health Inc., and Novotech Pty Ltd.
The increasing demand for new drugs, the rising cost of drug development, and increasingly outsourcing development and manufacturing activities are the major market drivers.
Stringent regulations and complex supply chains are the major market restraints.
The growing demand for new drugs to treat chronic diseases and the growing focus on personalized medicine are the major opportunities in the Pharmaceutical CRO and CDMO industry.